country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-181489

Copy Link Print Information

SARS-CoV-2 3CLpro-IN-35

SARS-CoV-2 3CLpro-IN-35 is a SARS-CoV-2 3CLpro inhibitor with an IC₅₀ of 0.15 μM. SARS-CoV-2 3CLpro-IN-35 inhibits the proliferation of bladder cancer cells, exerts anti-SARS-CoV-2 activity, and exhibits low cytotoxicity in fibroblasts. SARS-CoV-2 3CLpro-IN-35 is applicable to research related to SARS-CoV-2 infection and bladder cancer.

For research use only. We do not sell to patients.

CAS No.: 3023042-32-9
Formula: C₃₂H₂₄F₆O₆
Molecular Weight:618.52

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (273 KB)

SARS-CoV-2 3CLpro-IN-35 Chemical Structure

CAS No.: 3023042-32-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

In Vitro

SARS-CoV-2 3CLpro-IN-35 (Compound L3) (25 h) potently inhibits the infection of GFP-SARS-CoV-2-S-Psv in HK-2 cells, with an EC₅₀ of 2.82 μM^[1].
SARS-CoV-2 3CLpro-IN-35 (2-40 μM; 24 h) potently inhibits the proliferation of T24 bladder cancer cells in a concentration-dependent manner, with an IC₅₀ of 10.99 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

T24 human bladder cancer cells
Concentration:

2, 5, 10, 20 and 40 μM
Incubation Time:

24 h
Result:

Potently suppressed T24 bladder cancer cell proliferation in a concentration-dependent manner, with an IC₅₀ of 10.99 μM after 24 h of incubation.

Chemical Information

CAS No. 3023042-32-9
Molecular Weight 618.52
Formula C₃₂H₂₄F₆O₆
SMILES

O=C(CCC1=CC(C2=CC=C(C=C2)C(F)(F)F)=C(C(C3=C(C(C4=CC=C(C=C4)C(F)(F)F)=CC(CCC(O)=O)=C3)O)=C1)O)O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (273 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Shang LL, et al. Design and synthesis of dual-activity biphenyl inhibitors against SARS-CoV-2 and bladder cancer. Eur J Med Chem. 2026;306:118581. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote